PHIO

PhioC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.80

Analysis reference price unavailable

Analysis 2026-06-25 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.85

Analysis reference price unavailable

Analysis 2026-06-25 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.40

Analysis reference price unavailable

Analysis 2026-06-25 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-06-25

AI commentary

Recent flow was dominated by company-distributed Newsfile updates and investor-forum appearances rather than broad third-party validation, so headline visibility improved but evidence quality did not rise proportionally. The packet does not include usable social-sentiment coverage, so social context is not used as a positive signal. The most material update remains the May 7 earnings/business release tied to the 8-K, which reinforced completed Phase 1b dosing, pending final analysis, targeted Q2 FDA interaction, and runway into H1 2027 [#PR-EARNINGS-2026-05-08] [#SEC-8K-2026-05-07]. Thin analyst coverage and loose peers keep this as a monitoring-style biotech setup rather than a high-conviction bullish thesis.

RankAlpha Sentiment Codex - 2026-06-25

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-06-30eventPH-762 FDA interaction on next-step study designHigh impact

Management said the Phase 1b trial is complete, final data is being analyzed, and an FDA submission to seek guidance on next-step clinical study design for PH-762 was targeted for Q2 2026; any confirmation, delay, or unexpectedly burdensome feedback is the clearest near-term company-specific inflection [#PR-EARNINGS-2026-05-08] [#SEC-8K-2026-05-07].

2026-09-30catalystTranslation of completed Phase 1b data into a fundable development pathHigh impact

The company highlighted favorable safety and pathology data from the completed dose-escalation study, but final analysis is still pending; stronger-than-expected final framing could help de-risk PH-762, while ambiguous efficacy or added CMC/toxicology requirements would limit upside [#PR-EARNINGS-2026-05-08].

2026-12-31eventRunway and dilution clarity after ATM setupHigh impact

Phio reported about $17 million of cash at March 31, 2026, said prior financings extended runway into the first half of 2027, and disclosed an April 2026 ATM facility for up to $6.36 million; investors likely need clearer evidence that clinical progress can be funded without steep dilution [#PR-EARNINGS-2026-05-08].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-25 • Updated nightlySource: Internal modelMethodology